Skip to contentN
Northwest Biotherapeutics Inc
N
NWBONorthwest Biotherapeutics Inc Q3 2018 · 10-Q
Revenue$453.00K$453.00K+206.1% vs Q3 2017 Net Income$12.58M$12.58MN/M vs Q3 2017 EPS Diluted$0.02$0.02N/M vs Q3 2017 Operating Income-$9,319,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Northwest Biotherapeutics Inc · CIK 1072379 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-2057.2%+7492.1 pt vs Q3 2017
Net margin2776.6%+18500.2 pt vs Q3 2017
ended Sep 30, 2018 · filed Nov 16, 2018 · 47 d after period end